| 2.15 0.175 (8.86%) | 09-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.65 | 1-year : | 3.1 |
| Resists | First : | 2.27 | Second : | 2.65 |
| Pivot price | 1.9 |
|||
| Supports | First : | 1.57 |
Second : | 1.13 |
| MAs | MA(5) : | 2.05 |
MA(20) : | 1.78 |
| MA(100) : | 1.33 |
MA(250) : | 1.16 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 70.7 |
D(3) : | 71.2  |
| RSI | RSI(14): 73.1 |
|||
| 52-week | High : | 2.27 | Low : | 0.87 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CRDL ] has closed below upper band by 10.8%. Bollinger Bands are 86.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.18 - 2.19 | 2.19 - 2.2 |
| Low: | 1.92 - 1.93 | 1.93 - 1.94 |
| Close: | 2.13 - 2.15 | 2.15 - 2.16 |
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
Mon, 31 Aug 2026
Cardiol Therapeutics (TSX:CRDL) Falls 5.92% as Clinical Trial Uncertainty and Biotech Sector Volatility Pressure Investor Sentiment - kalkine.ca
Wed, 26 Aug 2026
B.Riley initiates Cardiol Therapeutics stock with buy rating on pericarditis drug potential - Investing.com
Tue, 25 Aug 2026
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Fri, 14 Aug 2026
MMCAP and MM Asset Management (CRDL) reveal 21.3M-share Cardiol Therapeutics stake - Stock Titan
Wed, 15 Jul 2026
H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 117 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 25.9 (%) |
| Shares Short | 2,250 (K) |
| Shares Short P.Month | 2,220 (K) |
| EPS | -0.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -91 % |
| Return on Equity (ttm) | -190.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -8.61 |
| PEG Ratio | 0 |
| Price to Book value | 14.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|